SYNOX THERAPEUTICS LIMITED

SynOx Therapeutics Ltd, founded in November 2020, is a specialised biopharmaceutical company dedicated to advancing treatments for rare, macrophage‑driven diseases. Its flagship programme centres on emactuzumab, a best‑in‑class monoclonal antibody that targets the colony‑stimulating factor‑1 receptor (CSF‑1R). By inhibiting this pathway, emactuzumab is being developed to address the unmet clinical needs of patients with tenosynovial giant cell tumours (TGCT) and other conditions where macrophages play a pivotal role.

The company’s focus is narrowly defined yet ambitious: to translate cutting‑edge scientific insight into life‑improving therapeutic options. SynOx combines industry‑leading expertise with a passion for patient‑centred care, aiming to give individuals greater control over their disease journey. Its work is driven by a commitment to deliver innovative, high‑quality medicines that can transform outcomes for those living with TGCT and related pathologies.